Mechanical Thrombectomy Preserves More Brain Tissue in Distal Stroke Vessels
A post hoc analysis of the DISTAL trial finds EVT plus medical therapy significantly improves brain tissue preservation in hard-to-reach vessel occlusions.
Summary
A new analysis from the DISTAL randomized trial examined whether mechanical thrombectomy — a procedure that physically removes blood clots — offers imaging-measurable benefits for strokes in smaller, harder-to-reach brain vessels. Researchers compared patients who received thrombectomy plus best medical treatment against those receiving medical treatment alone. Among 447 patients, those who underwent thrombectomy were 60% more likely to preserve at least 80% of the brain tissue initially at risk. When successful clot removal was achieved, the odds of preserving that tissue more than doubled. Critically, patients who preserved more brain tissue also had better functional outcomes at 90 days. These findings support using imaging-based endpoints to evaluate thrombectomy effectiveness in distal vessel strokes, a population where treatment benefit has been harder to demonstrate clinically.
Detailed Summary
Stroke caused by occlusion of medium or distal brain vessels presents a unique treatment challenge. These smaller, more peripheral vessels are harder to reach with endovascular tools, and clinical trial results for mechanical thrombectomy in this population have been mixed. Understanding whether thrombectomy meaningfully preserves brain tissue — even when clinical outcome differences are subtle — could reshape how we evaluate and deliver care.
This post hoc analysis drew from the DISTAL trial, a multicenter randomized clinical trial conducted across 55 hospitals in 11 countries between December 2021 and July 2024. Of 447 patients with baseline perfusion imaging and 24-hour follow-up imaging, 226 received endovascular treatment (EVT) plus best medical treatment (BMT) and 221 received BMT alone. The primary imaging outcome measured how much at-risk brain tissue was ultimately spared from infarction.
Patients receiving EVT plus BMT were 60% more likely to achieve a 'good imaging outcome' — defined as preserving at least 80% of initially at-risk tissue — compared to BMT alone (adjusted OR 1.6, 95% CI 1.1–2.3). When successful reperfusion was achieved, the odds more than doubled (aOR 2.5, 95% CI 1.3–4.8). Median absolute tissue preserved was also greater in the EVT group (23.6 mL vs. 14.8 mL). Patients achieving good imaging outcomes had meaningfully better 90-day clinical outcomes across both treatment groups.
These findings are clinically significant because they establish a quantifiable imaging bridge between procedural success and patient outcomes in distal vessel stroke — a population where demonstrating benefit has historically been difficult. Imaging endpoints may serve as more sensitive surrogate markers than clinical scales alone.
Caveats include the post hoc nature of the analysis, limiting causal inference. The summary is based on the abstract only, so full methodology, subgroup analyses, and adverse event data are not available for review.
Key Findings
- EVT plus medical therapy was 60% more likely to preserve ≥80% of at-risk brain tissue vs. medical therapy alone.
- Successful reperfusion more than doubled the odds of a good imaging outcome (aOR 2.5).
- Median brain tissue preserved was 23.6 mL with EVT vs. 14.8 mL with medical treatment alone.
- Good imaging outcomes at 24 hours strongly predicted better functional recovery at 90 days.
- Imaging-based endpoints may be more sensitive than clinical scales for evaluating distal vessel stroke treatment.
Methodology
Post hoc imaging analysis of the DISTAL randomized clinical trial, enrolling 447 patients across 55 hospitals in 11 countries. Patients required baseline perfusion imaging and 24-hour follow-up imaging. Primary outcome was the relative change in at-risk tissue volume versus final infarct volume at 24 hours.
Study Limitations
This is a post hoc analysis of the DISTAL trial, which limits causal inference and introduces potential selection bias. The summary is based on the abstract only, so full methodology, subgroup breakdowns, complication rates, and sensitivity analyses are unavailable. The imaging outcome threshold of 80% tissue preservation is a study-defined construct that requires further validation as a clinical surrogate.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.